714-1195

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
714 (USA) · Dr. Clarke
consented 2013-04-26

AEs

Serious

Dropout signal

–

Adverse events

severe assessed

Severe APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-13 (study day 18.0); relationship: PROBABLE

severe assessed

Severe APPLICATION SITE ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2013-05-13 (study day 18.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-17 (study day 22.0); relationship: PROBABLE

mild assessed

Mild DIARRHOEA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-12 (study day 17.0); relationship: REMOTE

mild assessed

Mild DIARRHOEA — outcome: RECOVERED/RESOLVED; onset 2013-05-12 (study day 17.0); relationship: REMOTE

mild assessed

Mild DYSURIA — outcome: RECOVERED/RESOLVED; onset 2013-07-25 (study day 91.0); relationship: REMOTE

moderate assessed

Moderate HYPERHIDROSIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-12 (study day 17.0); relationship: POSSIBLE

moderate assessed

Moderate HYPERHIDROSIS — outcome: RECOVERED/RESOLVED; onset 2013-05-12 (study day 17.0); relationship: POSSIBLE

mild assessed

Mild SOMNOLENCE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-14 (study day 19.0); relationship: NONE

Data queries

No data queries.